Canaccord raised the firm’s price target on Ceribell (CBLL) to $30 from $29 and keeps a Buy rating on the shares. The firm said they continue to be bullish on the Med-Tech sector heading into 2026. They point to strong underlying demand from an aging population, a focus on acute healthcare needs, the healthy pace of M&A, and a market that is receptive to IPOs as the foundation for our belief in our positive outlook in the upcoming year.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBLL:
- Ceribell, Inc. Extends Sunnyvale Office Leases
- Buy Rating Affirmed for Ceribell, Inc. Due to Innovative Neonate Technology and FDA Clearance
- Ceribell, Inc.’s Delirium Solution Gains Early FDA Clearance, Boosting Market Potential and Supporting Buy Rating
- Ceribell’s FDA Clearance Boosts Market Prospects and Expands Multi-Indication Platform
- Ceribell price target raised to $29 from $20 at TD Cowen